Table 11.
Cytotoxicity and antiviral activity of synthesized benzimidazole derivatives in HEL cell cultures.
| Comp. | Minimum cytotoxic concentrationa (μg/mL) | EC50b (μg/mL) |
||||
|---|---|---|---|---|---|---|
| Herpes simplex virus-1 (KOS) | Herpes simplex virus-2 (G) | Vaccinia virus | Vesicular stomatitis virus | Herpes simplex virus-1 TK− KOS ACVr | ||
| 1 | >100 | >100 | >100 | >100 | >100 | >100 |
| 2 | >100 | >100 | >100 | >100 | >100 | >100 |
| 3 | >100 | >100 | >100 | >100 | >100 | >100 |
| 4 | >100 | >100 | >100 | >100 | >100 | >100 |
| 5 | >100 | >100 | >100 | >100 | >100 | >100 |
| 6 | >100 | >100 | >100 | >100 | >100 | >100 |
| 7 | 100 | >20 | >20 | >20 | >20 | >20 |
| 8 | >100 | >100 | >100 | >100 | >100 | >100 |
| 9 | >100 | >100 | >100 | >100 | >100 | >100 |
| 10 | >100 | >100 | >100 | >100 | >100 | >100 |
| 11 | >100 | >100 | >100 | >100 | >100 | >100 |
| 12 | >100 | >100 | >100 | >100 | >100 | >100 |
| 13 | 100 | >20 | >20 | >20 | >20 | >20 |
| 14 | >100 | >100 | >100 | >100 | >100 | >100 |
| 15 | >100 | >100 | >100 | >100 | >100 | >100 |
| 16 | >100 | >100 | >100 | >100 | >100 | >100 |
| 17 | >100 | >100 | >100 | >100 | >100 | >100 |
| 18 | >100 | >100 | >100 | >100 | >100 | >100 |
| 19 | >100 | >100 | >100 | >100 | >100 | >100 |
| 20 | >100 | >100 | >100 | >100 | >100 | >100 |
| Brivudin (μM) | >250 | 0.08 | 250 | 112 | >250 | >250 |
| Ribavirin (μM) | >250 | 1 | 2 | 10 | >250 | 2 |
| Cidofovir (μM) | >250 | 0.4 | 0.2 | >250 | >250 | >250 |
| Ganciclovir (μM) | >100 | 0.03 | 0.03 | >100 | >100 | 58 |
a
Required to cause a microscopically detectable alteration of normal cell morphology.
b
Required to reduce virus-induced cytopathogenicity by 50%.